Ele Ferrannini
Overview
Explore the profile of Ele Ferrannini including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
395
Citations
24044
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Trico D, Chiriaco M, Nouws J, Vash-Margita A, Kursawe R, Tarabra E, et al.
Diabetes
. 2023 Oct;
73(6):941-952.
PMID: 37870826
Article Highlights:
12.
Rebelos E, Latva-Rasku A, Koskensalo K, Pekkarinen L, Saukko E, Ihalainen J, et al.
J Cereb Blood Flow Metab
. 2023 Oct;
44(3):407-418.
PMID: 37824728
The human brain undergoes metabolic adaptations in obesity, but the underlying mechanisms have remained largely unknown. We compared concentrations of often reported brain metabolites measured with magnetic resonance spectroscopy (H-MRS,...
13.
Paivarinta J, Anastasiou I, Koivuviita N, Sharma K, Nuutila P, Ferrannini E, et al.
J Clin Med
. 2023 Aug;
12(15).
PMID: 37568543
Thanks to technical advances in the field of medical imaging, it is now possible to study key features of renal anatomy and physiology, but so far poorly explored due to...
14.
Fortin E, Lundin M, Mellbin L, Norhammar A, Nasman P, Smetana S, et al.
Cardiovasc Diabetol
. 2023 Aug;
22(1):208.
PMID: 37568149
Background: Empagliflozin reduces the risk of cardiovascular disease (CVD) in patients with type 2 diabetes (T2DM) and high cardiovascular risk via mechanisms which have not been fully explained. The mechanisms...
15.
Gitelman S, Evans-Molina C, Guolo A, Mari A, Ferrannini E
Diabetes
. 2023 Jun;
72(9):1289-1296.
PMID: 37368990
Article Highlights: We undertook this study to better predict β-cell loss following type 1 diabetes diagnosis. We set out to answer whether β-cell glucose sensitivity (βGS) improves means to evaluate...
16.
Boulton A, Ferrannini E, Halban P
Diabetologia
. 2023 Jun;
66(8):1355-1356.
PMID: 37328553
No abstract available.
17.
Lu C, Donners M, Karel J, de Boer H, van Zonneveld A, den Ruijter H, et al.
Atherosclerosis
. 2023 May;
384:117123.
PMID: 37127497
Background And Aims: This study aims to identify sex-specific transcriptional differences and signaling pathways in circulating monocytes contributing to cardiovascular disease. Methods And Results: We generated sex-biased gene expression signatures...
18.
Ferrannini G, Pollock C, Natali A, Yavin Y, Mahaffey K, Ferrannini E
Cardiovasc Diabetol
. 2023 Apr;
22(1):100.
PMID: 37120538
Background: Obesity is an independent risk factor for cardiovascular disease (CVD) in patients with type 2 diabetes (T2D). However, it is not known to what extent weight fluctuations might be...
19.
Radovani B, Vuckovic F, Maggioni A, Ferrannini E, Lauc G, Gudelj I
Biomolecules
. 2023 Feb;
13(2).
PMID: 36830744
Coronary artery disease (CAD) is the most common cardiovascular disease (CVD), and previous studies have shown a significant association between N-glycosylation, a highly regulated posttranslational modification, and the development of...
20.
Biancalana E, Rossi C, Raggi F, Distaso M, Trico D, Baldi S, et al.
J Clin Endocrinol Metab
. 2023 Feb;
108(8):e567-e573.
PMID: 36794422
Context: Sodium glucose co-transporter-2 inhibitors exert clinically relevant cardiorenal protection. Among several mechanisms, inhibition of sodium-hydrogen exchanger-3 (NHE3) in proximal renal tubules has been proposed in rodents. Demonstration of this...